Announcements Trials
Browse Landscape

Phase

Phase 3 9Phase 2 7Phase NA 2Phase 2/3 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Magnetic Resonance Spectroscopy 13Specimen Handling 12Radiotherapy 8Doxorubicin 8Nivolumab 7Immunoglobulin G 6Disulfides 6Cisplatin 6Biopsy 6Radiation 5Platinum 5Paclitaxel 5Cytarabine 5Bevacizumab 51,2-diaminocyclohexaneplatinum II citrate 5atezolizumab 4Vincristine 4Taxes 4Prednisone 4Methotrexate 4Daunorubicin 4Cyclophosphamide 4Cetuximab 4Carboplatin 4prednylidene 3merphos 3liposomal doxorubicin 3deltacortene 3Temozolomide 3Radiotherapy, Intensity-Modulated 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NIH × pegaspargase × Clear all
NCT00720109 2020-04-13

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2/3 Completed
63 enrolled 13 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡